Stay updated on Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page.

Latest updates to the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 on the page. This appears to be a minor site revision.SummaryDifference0.1%

- Check20 days agoChange DetectedAdded Revision: v3.4.1 and removed Revision: v3.4.0.SummaryDifference0.1%

- Check27 days agoChange DetectedAdded glossary display option; added metadata labels 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0'. Removed older labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page shows a revision update from v3.3.3 to v3.3.4; there are no changes to study details, dates, or other content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a dedicated Locations section listing California, Massachusetts, and New York; removed separate state location headers and updated the revision from v3.3.2 to v3.3.3.SummaryDifference0.4%

- Check91 days agoChange DetectedPublications section updated to indicate items are automatically filled from PubMed. Revision tag updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page.